Human Organ-on-a-Chip Testing Platform OrganChip Alliance Receives EMA Recognition: Drug Toxicity Testing Can Fully Replace Animal Experiments for the First Time

Human Organ-on-a-Chip Testing Platform OrganChip Alliance Receives EMA Recognition

On October 28, 2030, the European Medicines Agency (EMA) officially announced recognition of organ-on-a-chip platform-generated drug toxicity data as alternative evidence for drug safety assessment. This means that when applying for new drug marketing authorization in the EU, pharmaceutical companies can use organ-on-a-chip data in place of traditional animal experiment data.

Organ-on-a-chip is a technology that cultivates human cells on microfluidic chips, capable of simulating the microenvironment and functions of human organs. The OrganChip Alliance is a standardized organ-on-a-chip testing platform jointly established by three companies — Emulate, Mimetas, and TissUse — providing standardized toxicity testing protocols covering five organs: liver, kidney, heart, lung, and brain.

The EMA's Head of Medicines Safety stated: "The predictive accuracy of organ-on-a-chip technology has reached or exceeded the level of animal experiments in multiple comparative studies. More importantly, organ-on-a-chip uses human cells, providing better extrapolation of results to humans."

The OrganChip Alliance's standardized testing protocols include acute toxicity testing (single high-dose exposure), chronic toxicity testing (repeated low-dose exposure, up to 28 days), and genotoxicity testing (mutagenic potential assessment). A single full-suite test costs approximately 150,000 euros, roughly on par with animal experiment costs.

Animal rights organization PETA welcomed the decision, calling it a "landmark moment in ending animal experimentation." The pharmaceutical industry has also broadly expressed support, as organ-on-a-chip testing cycles (approximately 2 to 4 weeks) are far shorter than animal experiments (approximately 3 to 6 months).